It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer. These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job [...]
Researchers at the Harvard Medical School investigated the effect of androgen deprivation in a preclinical mouse model of stable high grade prostatic intraepithelial neoplasia induced by the loss of the PTEN tumor suppressor. They found that androgen deprivation treatment of these mice accelerated the progression to invasive disease. Shidong Jia, M.D., Ph.D. And associates found [...]
There has been much discussion about the timing of treatments now that we have new drugs available to treat advanced prostate cancer. However, today’s technology does not allow us to know what the best sequencing of these drugs to maximize their efficacy would be, so we just punt along. We do not know whether or [...]
At the 2012 Genitourinary Cancers Symposium ASCO conference, Dr. Philip Kantoff (Dana-Farber Cancer Institute, Harvard Medical School Boston, MA) suggested taking a personalized approach to the individualized treatment plan for all men suffering from advanced prostate cancer. Dr. Kantoff said, “Few patients with advanced prostate cancer are currently cured with ADT (but anecdotally, long-term survival [...]
There were many themes running through the recent American Association of Cancer Researchers (AACR) conference that I just attended in Washington D.C. One significant theme running through the conference was the need to develop personalized medicine to be able to successfully control cancer. This leads us to the question, What is personalized medicine? [...]
